Autobio Diagnostics Co Ltd
SSE:603658
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
38.18
66.36
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Autobio Diagnostics Co Ltd
Autobio Diagnostics Co Ltd
Other Current Liabilities
Autobio Diagnostics Co Ltd
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Autobio Diagnostics Co Ltd
SSE:603658
|
Other Current Liabilities
¥649m
|
CAGR 3-Years
0%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
|
Other Current Liabilities
¥544.6m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Eyebright Medical Technology Beijing Co Ltd
SSE:688050
|
Other Current Liabilities
¥159.8m
|
CAGR 3-Years
41%
|
CAGR 5-Years
82%
|
CAGR 10-Years
N/A
|
|
|
S
|
Shandong Pharmaceutical Glass Co Ltd
SSE:600529
|
Other Current Liabilities
¥518.7m
|
CAGR 3-Years
33%
|
CAGR 5-Years
11%
|
CAGR 10-Years
18%
|
|
|
Winner Medical Co Ltd
SZSE:300888
|
Other Current Liabilities
¥626.3m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
Other Current Liabilities
¥277.8m
|
CAGR 3-Years
0%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
Autobio Diagnostics Co Ltd
Glance View
Autobio Diagnostics Co., Ltd. is a company that has carved a distinctive niche in the biotechnology landscape, particularly within the realm of in-vitro diagnostics (IVD). The company's journey began with a mission to enhance healthcare by providing advanced diagnostic tools that offer precise and timely results. Specializing in the development, production, and distribution of diagnostic reagents and instruments, Autobio has dedicated itself to innovation and quality in medical diagnostics. Its expansive product portfolio covers areas such as immunoassay detection, microbiology, clinical chemistry, and molecular diagnostics, catering to both hospital laboratories and independent labs. The firm prides itself on adopting cutting-edge technology to create solutions that are not only efficient and cost-effective but also align with global health standards. The financial heartbeat of Autobio lies in its strategic approach to generating revenue through diverse streams. With a keen focus on research and development, the company continually innovates its product lines, thereby sustaining a competitive edge in the fast-evolving diagnostics market. Additionally, its revenue model capitalizes heavily on the consumables-market; reagents and test kits are used in routine diagnostics, creating a recurring income source as these products need constant replenishment. By expanding its geographic footprint through partnerships and direct sales channels, Autobio enhances its market reach, strengthening its ability to leverage scale economies. Moreover, the company’s commitment to maintaining strong customer relationships through robust after-sales service and technical support has built a loyal base, further fueling its revenue engine.
See Also
What is Autobio Diagnostics Co Ltd's Other Current Liabilities?
Other Current Liabilities
649m
CNY
Based on the financial report for Sep 30, 2024, Autobio Diagnostics Co Ltd's Other Current Liabilities amounts to 649m CNY.
What is Autobio Diagnostics Co Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
14%
Over the last year, the Other Current Liabilities growth was -22%.
You don't have any saved screeners yet